Toxicity and metabolic aspects

Date 01 March 2014
Event Signalling Pathways in Cancer 2014
Session Clinical development of PI3K/AKT/mTOR inhibitors
Topics Drug Development
Complications of Treatment
Presenter Philippe Bedard
Authors P. Bedard
  • Division Of Medical Oncology & Hematology, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA